Skip to main content

Table 2 Relative gene expression and variability of candidate reference genes

From: Expression of target and reference genes in Daphnia magna exposed to ibuprofen

 

Relative expressiona

  

Gene

Control

20 mg IB l-1

40 mg IB l-1

80 mg IB l-1

Gene variabilityb

Amplification efficiency (E)a

Act

1.000 ± 0.078

0.963 ± 0.035

1.030 ± 0.044

1.001 ± 0.040

0.119

0.795 ± 0.066

Atb

1.000 ± 0.129

0.896 ± 0.126

0.885 ± 0.095

0.613 ± 0.045 c

-

1.010 ± 0.016

Cyp

1.000 ± 0.040

0.949 ± 0.103

0.900 ± 0.015

0.817 ± 0.067 d

-

1.038 ± 0.016

GAPDH

1.000 ± 0.093

0.914 ± 0.059

0.919 ± 0.047

0.879 ± 0.067

0.098

0.946 ± 0.029

SDH

1.000 ± 0.145

0.889 ± 0.170

0.950 ± 0.180

1.027 ± 0.026

0.160

0.992 ± 0.015

TBP

1.000 ± 0.096

0.786 ± 0.176

0.788 ± 0.153

1.038 ± 0.084

0.192

0.925 ± 0.016

WARS

1.000 ± 0.117

0.954 ± 0.098

0.906 ± 0.060

0.955 ± 0.081

0.136

0.922 ± 0.064

UBC

1.000 ± 0.040

0.995 ± 0.095

1.024 ± 0.016

0.888 ± 0.097

0.098

1.034 ± 0.013

18S

1.000 ± 0.279

2.096 ± 1.074

2.506 ± 1.640

2.204 ± 0.910

0.430

0.853 ± 0.089

28S

1.000 ± 0.261

1.247 ± 0.445

1.410 ± 0.560

1.457 ± 0.616

0.313

0.846 ± 0.020

  1. Gene name abbreviations as Table 1.
  2. aValues are mean ± SD (IB refers to ibuprofen). Expression levels are displayed relative to the mean control level.
  3. bGene variability is estimated by geNorm as the variation (SD) of a given reference gene relative to the remaining reference genes (Atb and Cyp are not included in the analysis as they are significantly down-regulated by IB).
  4. cHighest treatment (80 mg IB l-1) significantly different from any other treatment (p < 0.05).
  5. dHighest treatment (80 mg IB l-1) significantly different from control (p < 0.05).